Absci Corporation (ABSI)
$
2.62
-0.21 (-8.02%)
Key metrics
Financial statements
Free cash flow per share
-0.6013
Market cap
391.8 Million
Price to sales ratio
94.6714
Debt to equity
0.0418
Current ratio
4.3867
Income quality
0.6744
Average inventory
0
ROE
-0.6021
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Absci Corporation, a drug and target discovery company founded in 2011 and headquartered in Vancouver, Washington, provides biologic drug candidates and production cell lines for partners in the United States using its integrated drug creation platform. This platform unifies the processes of drug discovery and cell line development, allowing for the efficient creation of biologics. The company recorded an operating income of -$108,888,000.00 reflecting its earnings from core operations. Furthermore, with a weighted average number of diluted shares outstanding at 110,239,870.00 the company illustrates potential dilution effects. Absci reported an income before tax of -$103,036,000.00 showcasing its pre-tax profitability while earning an interest income of $0.00 highlighting the effectiveness of its financial investments. The company achieved a revenue of $4,534,000.00 indicating its niche market focus and commitment to advancing drug development. In the financial landscape, Absci’s stock is affordable at $2.66 making it suitable for budget-conscious investors. The stock has a high average trading volume of 4,793,366.00 indicating strong liquidity, which can attract a diverse range of investors. With a market capitalization of $391,750,260.00 the company is classified as a small-cap player, positioning it as a dynamic entity within the biotechnology sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with innovative solutions. Additionally, Absci belongs to the Healthcare sector, driving innovation and growth, and emphasizing its pivotal role in shaping the future of drug discovery and development.
Is Absci Corporation (ABSI) a good investment?
Investing in Absci Corporation (ABSI) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Absci Corporation (ABSI)'s stock forecast?
Analysts predict Absci Corporation stock to fluctuate between $2.01 (low) and $6.33 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Absci Corporation's market capitalization?
As of 2025-08-20, Absci Corporation's market cap is $391,750,260, based on 149,523,000 outstanding shares.
How does Absci Corporation compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Absci Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Absci Corporation (ABSI) stock?
To buy Absci Corporation (ABSI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABSI. Place an order (Market, Limit, etc.).
What is the best time to invest in Absci Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Absci Corporation perform in the last earnings report?
Revenue: $4,534,000 | EPS: -$0.94 | Growth: -21.67%.
Where can I find Absci Corporation's investor relations reports?
Visit https://www.absci.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Absci Corporation?
You can explore historical data from here
What is the all-time high and low for Absci Corporation stock?
All-time high: $28.28 (2021-08-09) | All-time low: $1.11 (2023-10-26).
What are the key trends affecting Absci Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Absci Corporation (NASDAQ:ABSI ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Alexander Khan - VP of Finance & Head of Investor Relations Christian Stegmann - Senior Vice President of Drug Creation Sean McClain - Founder, CEO, President & Director Zachariah Jonasson - Chief Business Officer & CFO Conference Call Participants Alexander Xenakis - Unidentified Company Truist Securities - Unidentified Company Arseniy Shabashvili - Guggenheim Securities, LLC, Research Division Brendan Mychal Smith - TD Cowen, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Gil Joseph Blum - Needham & Company, LLC, Research Division Morgan K. Gryga - Morgan Stanley, Research Division Steven Craig Dechert - KeyBanc Capital Markets Inc., Research Division Swayampakula Ramakanth - H.C.
zacks.com
Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.
globenewswire.com
VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten public offering of 16,670,000 shares of its common stock at a public offering price of $3.00 per share, before deducting underwriting discounts and commissions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 2,500,500 shares of its common stock on the same terms and conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Absci.
globenewswire.com
VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, announced today that it has commenced an underwritten public offering of $50 million of shares of its common stock. Absci also intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Absci.
seekingalpha.com
Absci Corporation (NASDAQ:ABSI ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and Chief Executive Officer Zach Jonasson - Chief Financial Officer and Chief Business Officer Christian Stegmann - Senior Vice President of Drug Creation Conference Call Participants Arseniy Shabashvili - Guggenheim Securities Brendan Smith - TD Cowen Gil Blum - Needham & Company George Farmer - Scotiabank Debanjana Chatterjee - Jones Li Chen - H.C. Wainwright Operator Thank you for standing by, and welcome to Absci's First Quarter 2025 Business Update and Financial and Operating Results Conference Call.
zacks.com
Absci Corporation (ABSI) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.22 per share a year ago.
seekingalpha.com
Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Despite weak financials, Absci's internal pipeline, including ABS-101 and ABS-201, offers potential upside but increases burn rates and development risks. Strategic partnerships, like those with AMD and AstraZeneca, validate Absci's platform but have yet to generate significant revenue.
benzinga.com
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
seekingalpha.com
Absci Corporation (NASDAQ:ABSI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Alex Khan - VP of Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and CBO Christian Stegmann - SVP of Drug Creation Conference Call Participants Arseniy Shabashvili - Guggenheim Vikram Purohit - Morgan Stanley Gil Blum - Needham & Company Debanjana Chatterjee - Jones Operator Thank you for standing by and welcome to Absci's Fourth Quarter and Full Year 2024 Business Update and Financial Operating Results Conference call. At this time, all participants are in listen-only mode.
benzinga.com
Needham analyst has initiated coverage on Absci Corporation ABSI, a drug and target discovery company that harnesses deep learning AI and synthetic biology to expand proteins' therapeutic potential.
See all news
